Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma

  1. Usmani, S.Z.
  2. Nahi, H.
  3. Legiec, W.
  4. Grosicki, S.
  5. Vorobyev, V.
  6. Spicka, I.
  7. Hungria, V.
  8. Korenkova, S.
  9. Bahlis, N.J.
  10. Flogegard, M.
  11. Bladé, J.
  12. Moreau, P.
  13. Kaiser, M.
  14. Iida, S.
  15. Laubach, J.
  16. Magen, H.
  17. Cavo, M.
  18. Hulin, C.
  19. White, D.
  20. De Stefano, V.
  21. Lantz, K.
  22. O'Rourke, L.
  23. Heuck, C.
  24. Delioukina, M.
  25. Qin, X.
  26. Nnane, I.
  27. Qi, M.
  28. Mateos, M.-V.
  29. Show all authors +
Journal:
Haematologica

ISSN: 1592-8721

Year of publication: 2022

Volume: 107

Issue: 10

Pages: 2408-2417

Type: Article

DOI: 10.3324/HAEMATOL.2021.279459 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals